Eli Lilly and Company (NYSE:LLY) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 12.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,235 shares of the company’s stock after selling 4,762 shares during the period. Great Lakes Advisors LLC’s holdings in Eli Lilly and Company were worth $30,089,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Tidemark LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $29,000. Core Wealth Advisors Inc. increased its position in shares of Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the last quarter. Lynx Investment Advisory purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $32,000. LGT Financial Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $36,000. Finally, Frank Rimerman Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $37,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. Jefferies Financial Group raised their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research note on Thursday. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, August 19th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Stock Performance

LLY stock traded down $10.04 on Friday, hitting $902.71. The company’s stock had a trading volume of 3,439,999 shares, compared to its average volume of 3,063,074. The stock has a market cap of $857.94 billion, a price-to-earnings ratio of 132.95, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. The firm has a 50 day moving average of $895.97 and a two-hundred day moving average of $827.49. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Equities analysts predict that Eli Lilly and Company will post 16.51 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 15,022 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $882.47, for a total transaction of $13,256,464.34. Following the transaction, the insider now directly owns 97,778,788 shares in the company, valued at $86,286,847,046.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 737,410 shares of company stock valued at $669,719,100. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.